Alkermes (NASDAQ: ALKS) director exercises options and sells shares under 10b5-1 plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Alkermes plc director Shane Cooke reported exercising employee stock options and selling the resulting shares. On 02/02/2026, he exercised 61,200 employee stock options at an exercise price of $31.64 per share as the options approached their 02/28/2026 expiration.

That same day, he sold 29,087 ordinary shares at a weighted average price of $34.3382 per share and 32,113 ordinary shares at a weighted average price of $34.7796 per share in multiple transactions. After these trades, Cooke directly owned 103,744 ordinary shares of Alkermes plc.

The filing notes that the exercise and sale of expiring options were executed under a Rule 10b5-1 trading plan adopted on 02/27/2025, and that the options were fully vested in accordance with their terms.

Insider Trade Summary

Net Seller: 61,200 shares ($2,115,673)

Net Sell 4 txns

Insider Cooke Shane

Role Director

Sold 61,200 shs ($2.12M)

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Buy)	61,200	$0.00	--
Exercise	Ordinary Shares	61,200	$31.64	$1.94M
Sale	Ordinary Shares	29,087	$34.3382	$999K
Sale	Ordinary Shares	32,113	$34.7796	$1.12M

Holdings After Transaction: Employee Stock Option (Right to Buy) — 0 shares (Direct); Ordinary Shares — 164,944 shares (Direct)

Footnotes (1)

This exercise and sale of expiring options was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/27/25. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.6923 to $34.69. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.70 to $34.91. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. These options are fully vested in accordance with their terms.

Form 4 Insider Transactions: What Each Field Means →

02/02/2026 - 08:48 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cooke Shane

(Last)

(First)

(Middle)

CONNAUGHT HOUSE

1 BURLINGTON ROAD

(Street)

DUBLIN

4 Ireland

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Alkermes plc. [ ALKS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	02/02/2026		M⁽¹⁾		61,200	A	$31.64	164,944	D
Ordinary Shares	02/02/2026		S⁽¹⁾		29,087	D	$34.3382⁽²⁾	135,857	D
Ordinary Shares	02/02/2026		S⁽¹⁾		32,113	D	$34.7796⁽³⁾	103,744	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (Right to Buy)	$31.64	02/02/2026		M⁽¹⁾			61,200	⁽⁴⁾	02/28/2026	Ordinary Shares	61,200	$0	0	D

Explanation of Responses:

1. This exercise and sale of expiring options was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/27/25.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.6923 to $34.69. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.70 to $34.91. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

4. These options are fully vested in accordance with their terms.

	/s/ Shantale Greenson, attorney-in-fact for Shane Cooke	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did Alkermes (ALKS) director Shane Cooke report?

Shane Cooke reported exercising 61,200 stock options and selling the resulting Alkermes ordinary shares. The transactions occurred on February 2, 2026 and involved expiring, fully vested employee stock options executed under a pre-established Rule 10b5-1 trading plan.

How many Alkermes (ALKS) options did Shane Cooke exercise and at what price?

Shane Cooke exercised 61,200 Alkermes employee stock options at an exercise price of $31.64 per share. These options were fully vested and were scheduled to expire on February 28, 2026, prompting the exercise and related share sales.

At what prices did Shane Cooke sell Alkermes (ALKS) shares on February 2, 2026?

Cooke sold 29,087 Alkermes ordinary shares at a weighted average price of $34.3382 and 32,113 shares at a weighted average price of $34.7796. Each reported average reflects multiple trades within narrow price ranges disclosed in the footnotes.

How many Alkermes (ALKS) shares does Shane Cooke own after these transactions?

After the February 2, 2026 transactions, Shane Cooke directly owns 103,744 Alkermes ordinary shares. This balance reflects his holdings following the option exercise and the subsequent sales of shares reported in this Form 4 filing.

Were Shane Cooke’s Alkermes (ALKS) trades under a Rule 10b5-1 plan?

Yes. The filing states the exercise and sale of expiring options were carried out under a Rule 10b5-1 trading plan adopted by Shane Cooke on February 27, 2025. Such plans pre-schedule trades to help manage insider trading concerns.

What do the weighted average prices in Shane Cooke’s Alkermes (ALKS) sales mean?

The reported prices of $34.3382 and $34.7796 are weighted averages across multiple trades. The footnotes explain that individual sale prices ranged from $33.6923 to $34.69 and from $34.70 to $34.91, and detailed breakdowns are available upon request.